CA2455939C - Sucralose formulations to mask unpleasant tastes - Google Patents

Sucralose formulations to mask unpleasant tastes Download PDF

Info

Publication number
CA2455939C
CA2455939C CA2455939A CA2455939A CA2455939C CA 2455939 C CA2455939 C CA 2455939C CA 2455939 A CA2455939 A CA 2455939A CA 2455939 A CA2455939 A CA 2455939A CA 2455939 C CA2455939 C CA 2455939C
Authority
CA
Canada
Prior art keywords
composition
active compound
pharmaceutically active
group
sucralose
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
CA2455939A
Other languages
English (en)
French (fr)
Other versions
CA2455939A1 (en
Inventor
David Jaeger
Jay Dickerson
Annabelle Trimmer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
PF Consumer Healthcare 1 LLC
Original Assignee
Wyeth LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23195896&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA2455939(C) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Wyeth LLC filed Critical Wyeth LLC
Publication of CA2455939A1 publication Critical patent/CA2455939A1/en
Application granted granted Critical
Publication of CA2455939C publication Critical patent/CA2455939C/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7012—Compounds having a free or esterified carboxyl group attached, directly or through a carbon chain, to a carbon atom of the saccharide radical, e.g. glucuronic acid, neuraminic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/10—Expectorants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pulmonology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Otolaryngology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA2455939A 2001-07-31 2002-07-31 Sucralose formulations to mask unpleasant tastes Expired - Lifetime CA2455939C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US30891201P 2001-07-31 2001-07-31
US60/308,912 2001-07-31
PCT/US2002/024298 WO2003011306A1 (en) 2001-07-31 2002-07-31 Sucralose formulations to mask unpleasant tastes

Publications (2)

Publication Number Publication Date
CA2455939A1 CA2455939A1 (en) 2003-02-13
CA2455939C true CA2455939C (en) 2011-03-22

Family

ID=23195896

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2455939A Expired - Lifetime CA2455939C (en) 2001-07-31 2002-07-31 Sucralose formulations to mask unpleasant tastes

Country Status (13)

Country Link
US (2) US20060121066A1 (enExample)
EP (1) EP1411955A4 (enExample)
JP (2) JP2004538309A (enExample)
AU (1) AU2002324579B2 (enExample)
BR (1) BR0211794A (enExample)
CA (1) CA2455939C (enExample)
CL (1) CL2004000208A1 (enExample)
CO (1) CO5560580A2 (enExample)
CR (1) CR7264A (enExample)
EC (1) ECSP044995A (enExample)
MX (1) MXPA04001026A (enExample)
NZ (1) NZ530889A (enExample)
WO (1) WO2003011306A1 (enExample)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030211136A1 (en) * 1998-09-25 2003-11-13 Neema Kulkarni Fast dissolving orally consumable films containing a sweetener
JP4814636B2 (ja) * 2004-01-29 2011-11-16 大日本住友製薬株式会社 ビグアナイド系薬物の内服製剤
PL2486942T3 (pl) 2004-11-24 2019-05-31 Meda Pharmaceuticals Inc Kompozycje zawierające azelastynę oraz sposoby ich stosowania
US20070020330A1 (en) * 2004-11-24 2007-01-25 Medpointe Healthcare Inc. Compositions comprising azelastine and methods of use thereof
US8435588B2 (en) * 2005-11-23 2013-05-07 The Coca-Cola Company High-potency sweetener composition with an anti-inflammatory agent and compositions sweetened therewith
US9101160B2 (en) 2005-11-23 2015-08-11 The Coca-Cola Company Condiments with high-potency sweetener
US8940796B2 (en) * 2006-02-21 2015-01-27 Wyeth Llc Phenylephrine liquid formulations
US10022339B2 (en) 2006-04-21 2018-07-17 The Procter & Gamble Company Compositions and methods useful for treatment of respiratory illness
US20070249727A1 (en) * 2006-04-21 2007-10-25 The Proctor & Gamble Company Compositions and kits useful for treatment of respiratory illness
US20080014274A1 (en) 2006-07-14 2008-01-17 Wyeth Enhanced stability phenylephrine liquid compositions
US9005652B2 (en) 2006-07-25 2015-04-14 Wyeth Chewable tablet containing phenylephrine
US8017168B2 (en) 2006-11-02 2011-09-13 The Coca-Cola Company High-potency sweetener composition with rubisco protein, rubiscolin, rubiscolin derivatives, ace inhibitory peptides, and combinations thereof, and compositions sweetened therewith
US8323695B2 (en) * 2007-08-13 2012-12-04 Mcneil-Ppc, Inc. Method for stabilizing phenylephrine
JP2013053136A (ja) * 2011-08-09 2013-03-21 Taisho Pharmaceutical Co Ltd 内服液剤
WO2013084090A1 (en) 2011-12-09 2013-06-13 Wockhardt Limited Oral liquid concentrate comprising brompheniramine, pseudoephedrine and dextromethorphan
WO2013088271A1 (en) 2011-12-14 2013-06-20 Wockhardt Limited Modified release liquid pharmaceutical composition comprising bromopheniramine, pseudoephedrine and dextromethorphan
US8568747B1 (en) 2012-10-05 2013-10-29 Silvergate Pharmaceuticals, Inc. Enalapril compositions
US9549909B2 (en) 2013-05-03 2017-01-24 The Katholieke Universiteit Leuven Method for the treatment of dravet syndrome
ES2929945T3 (es) * 2013-11-13 2022-12-05 National Defense Education And Res Foundation Nueva composición de un compuesto de acetaminofeno sin efectos secundarios sobre el hígado
JP6565334B2 (ja) * 2014-06-18 2019-08-28 大正製薬株式会社 固形製剤
CN105640956B (zh) * 2014-11-14 2018-09-14 澳美制药厂有限公司 不含防腐剂的复方磷酸可待因组合口服液及其制备方法
GR1009069B (el) * 2015-01-05 2017-07-07 Λαμδα Φαρμακευτικα Εργαστηρια Εφαρμοσμενης Ερευνας & Αναπτυξης Α.Ε. Ποσιμα διαλυματα υψηλης συγκεντρωσης που περιεχουν υδροχλωρικη ρανιτιδινη
US20160317497A1 (en) * 2015-05-01 2016-11-03 Trinity Ent And Facial Aesthetics Flavored analgesic and decongestant spray
JP6794758B2 (ja) * 2015-10-21 2020-12-02 大正製薬株式会社 経口液体医薬組成物
EP3181150A1 (de) * 2015-12-19 2017-06-21 Analyticon Discovery GmbH Pharmazeutische zubereitungen
US10689324B2 (en) 2015-12-22 2020-06-23 Zogenix International Limited Metabolism resistant fenfluramine analogs and methods of using the same
DK3800177T3 (da) 2015-12-22 2025-03-31 Zogenix International Ltd Fenfluramin-sammensætninger og fremgangsmåder til fremstilling af samme
US9669008B1 (en) 2016-03-18 2017-06-06 Silvergate Pharmaceuticals, Inc. Enalapril formulations
GB2551971B (en) * 2016-06-29 2020-09-16 Syri Ltd Taste masked liquid pharmaceutical composition of mebeverine or pharmaceutically acceptable salts thereof
RU2021106383A (ru) 2016-08-24 2021-04-05 Зодженикс Интернэшнл Лимитед Состав для ингибирования образования агонистов 5-ht2b и способы его применения
US11234897B2 (en) 2017-03-27 2022-02-01 DXM Pharmaceutical, Inc. Packaged multi-dose liquid dextromethorphan hydrobromide formulation
US10682317B2 (en) 2017-09-26 2020-06-16 Zogenix International Limited Ketogenic diet compatible fenfluramine formulation
CA3097335A1 (en) 2018-05-11 2019-11-14 Zogenix International Limited Compositions and methods for treating seizure-induced sudden death
JP6858729B2 (ja) * 2018-05-25 2021-04-14 ▲財▼▲団▼法人国防教育研究基金会Ｎａｔｉｏｎａｌ Ｄｅｆｅｎｓｅ Ｅｄｕｃａｔｉｏｎ Ａｎｄ Ｒｅｓｅａｒｃｈ Ｆｏｕｎｄａｔｉｏｎ 肝臓に対する副作用がない、新しいアセトアミノフェン複合組成
US10517841B1 (en) 2018-06-14 2019-12-31 Zogenix International Limited Compositions and methods for treating respiratory depression with fenfluramine
WO2020105005A1 (en) 2018-11-19 2020-05-28 Zogenix International Limited Methods of treating rett syndrome using fenfluramine
WO2020251914A2 (en) * 2019-06-09 2020-12-17 DXM Pharmaceutical, Inc. Multi-dose concentrated liquid compositions
US12053447B2 (en) 2019-06-25 2024-08-06 NuBioPharma, LLC Oral solution and powder to liquid compositions of balsalazide
CN110302149A (zh) * 2019-08-07 2019-10-08 北京博达绿洲医药科技研究有限公司 一种适合4-11岁儿童服用抗感冒药物及其制备方法
CN110279695B (zh) * 2019-08-07 2022-04-08 北京博智绿洲医药科技有限公司 一种治疗流涕、鼻塞等感冒症状的药物组合物及其制备方法和用途
CN110327339A (zh) * 2019-08-07 2019-10-15 北京博达绿洲医药科技研究有限公司 一种复方右美沙芬口服溶液及其制备方法和用途
CN112439072A (zh) * 2019-08-29 2021-03-05 鲁南制药集团股份有限公司 一种掩味组合物及其制备方法、用途
US11612574B2 (en) 2020-07-17 2023-03-28 Zogenix International Limited Method of treating patients infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
CN117122562A (zh) * 2022-05-21 2023-11-28 山东百诺医药股份有限公司 一种美芬那敏铵口服溶液

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4552899A (en) * 1984-04-09 1985-11-12 Analgesic Associates Cough/cold mixtures comprising non-steroidal anti-inflammatory drugs
US4892877A (en) * 1987-10-27 1990-01-09 Richardson-Vicks Inc. Antitussive liquid compositions containing phenol
US5013716A (en) * 1988-10-28 1991-05-07 Warner-Lambert Company Unpleasant taste masking compositions and methods for preparing same
NZ234143A (en) * 1989-06-28 1991-10-25 Mcneil Ppc Inc Aqueous pharmaceutical suspension formulation for administering substantially insoluble pharmaceutical agents
NZ240818A (en) * 1990-12-14 1993-08-26 Mcneil Ppc Inc Liquid sucralose concentrate compositions containing preservative, buffer and liquid
US5164398A (en) * 1991-04-01 1992-11-17 Merck & Co., Inc. Ibuprofen-antitussive combinations
US5272137A (en) * 1992-02-14 1993-12-21 Mcneil-Pfc, Inc. Aqueous pharmaceutical suspension for pharmaceutical actives
US5422508A (en) * 1992-09-21 1995-06-06 Siliconix Incorporated BiCDMOS structure
FI941777L (fi) * 1993-04-16 1994-10-17 Mcneil Ppc Inc Vesipitoinen farmaseuttinen suspensio ja menetelmä sen valmistamiseksi
AU706890B2 (en) * 1994-01-24 1999-07-01 Procter & Gamble Company, The Process for solubilizing difficultly soluble pharmaceutical actives
US5458879A (en) * 1994-03-03 1995-10-17 The Procter & Gamble Company Oral vehicle compositions
US5773647A (en) * 1997-02-07 1998-06-30 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
US5885594A (en) * 1997-03-27 1999-03-23 The Procter & Gamble Company Oral compositions having enhanced mouth-feel
JP2000135055A (ja) * 1998-10-29 2000-05-16 Sanei Gen Ffi Inc 乳感の向上した乳含有製品
CN1211085C (zh) * 1999-09-29 2005-07-20 宝洁公司 稳定性改善的组合物
JP2001106639A (ja) * 1999-10-04 2001-04-17 Taisho Pharmaceut Co Ltd 経口用組成物
DE19961897A1 (de) * 1999-12-20 2001-06-28 Basf Ag Verwendung eines Filmüberzuges als geschmacksmaskierendes Coating von pharmazeutischen Darreichungsformen

Also Published As

Publication number Publication date
CL2004000208A1 (es) 2005-03-18
ECSP044995A (es) 2004-04-28
CO5560580A2 (es) 2005-09-30
EP1411955A4 (en) 2006-07-05
JP2010090142A (ja) 2010-04-22
MXPA04001026A (es) 2005-06-20
WO2003011306A1 (en) 2003-02-13
NZ530889A (en) 2005-03-24
CA2455939A1 (en) 2003-02-13
AU2002324579B2 (en) 2007-11-15
US20110136851A1 (en) 2011-06-09
BR0211794A (pt) 2004-11-03
US20060121066A1 (en) 2006-06-08
EP1411955A1 (en) 2004-04-28
JP2004538309A (ja) 2004-12-24
CR7264A (es) 2004-05-17

Similar Documents

Publication Publication Date Title
AU2002324579B2 (en) Sucralose formulations to mask unpleasant tastes
AU2002324579A1 (en) Sucralose formulations to mask unpleasant tastes
US5837285A (en) Fast soluble tablet
DE69622991T2 (de) Geschmacksmaskierende flüssigkeiten
DE69913138T2 (de) Stabilisierte zusammensetzung mit nootropen wirkstoffen
US8202538B2 (en) Orally disintegrating layered compositions
DE69226950T2 (de) Kapsel mit Langzeitwirkung fuer die Adhäsion im Gastrointestinaltrakt
US20110021588A1 (en) Sublingual dexmeditomidine compositions and methods of use thereof
US20060134199A1 (en) Tablet quickly melting in oral cavity
DE3538429A1 (de) Pulver mit gesteuerter freisetzung, verfahren zu dessen herstellung und dieses enthaltende pharmazeutische zusammensetzung
RU2314801C2 (ru) Композиция, содержащая парацетамол и маскирующий горечь компонент
WO1996003976A1 (en) Tastemasked liquid pharmaceutical delivery system
US11931413B2 (en) Dextromethorphan and guaifenesin syrup formulation or suspension
CH662734A5 (de) Antischnarchmittel.
JP2004196786A (ja) 難溶性抗ウイルス成分含有水溶性外用剤組成物
JPH10167988A (ja) 経口液剤
PL168968B1 (en) Method of manufacturing an antitussive drug
US20060198856A1 (en) Ibuprofen suspension stabilized with docusate sodium
EP1696874A1 (de) Brausezubereitung einer basischen arzneilich wirksamen substanz
JPH10306038A (ja) ブロムヘキシン含有液剤
JPH07116039B2 (ja) 安定な塩酸トリメトキノール内用液剤
JPH10203971A (ja) 水性経口液剤
JPS63313734A (ja) シロツプ剤
DE4422938A1 (de) Neue Weichgelatinekapseln
Miller Remedies for Common Cold Symptoms: Making sense of myriad drugs

Legal Events

Date Code Title Description
EEER Examination request
MKEX Expiry

Effective date: 20220802